(Q33378691)

26 July 2017

title

Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma (English)

1 reference

malignant pleural mesothelioma

26 July 2017

main subject

1 reference

Federico Cappuzzo

7

0 references

Armando Santoro

object named as

Armando Santoro

10

1 reference

ORCID Public Data File 2021

author name string

Paolo A Zucali

1

1 reference

26 July 2017

Giovanni L Ceresoli

2

1 reference

26 July 2017

Isabella Garassino

3

1 reference

26 July 2017

Fabio De Vincenzo

4

1 reference

26 July 2017

Raffaele Cavina

5

1 reference

26 July 2017

Elisabetta Campagnoli

6

1 reference

26 July 2017

Silvia Salamina

8

1 reference

26 July 2017

Hector J Soto Parra

9

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 April 2008

1 reference

26 July 2017

number of pages

7

1 reference

inferred from page(s)

published in

Cancer

1 reference

26 July 2017

volume

112

1 reference

26 July 2017

issue

7

1 reference

26 July 2017

page(s)

1555-1561

1 reference

A generalized Wilcoxon test for comparing arbitrarily singly-censored samples

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23337

The European mesothelioma epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23337

7 January 2021

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23337

7 January 2021

Phase II Study of Pemetrexed With and Without Folic Acid and Vitamin B12 as Front-Line Therapy in Malignant Pleural Mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23337

7 January 2021

Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23337

7 January 2021

Phase II trial of ZD0473 as second-line therapy in mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23337

7 January 2021

Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23337

7 January 2021

Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23337

7 January 2021

Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23337

7 January 2021

Pemetrexed as second-line treatment in malignant pleural mesothelioma after platinum-based first-line treatment.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23337

7 January 2021

Pemetrexed and cisplatin for malignant pleural mesothelioma: a new standard of care?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23337

7 January 2021

The role of gemcitabine in the treatment of malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23337

7 January 2021

Phase II study of vinorelbine in patients with malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23337

7 January 2021

Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23337

7 January 2021

A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23337

7 January 2021

Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23337

7 January 2021

Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23337

7 January 2021

Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23337

7 January 2021

Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23337

7 January 2021

Phase II trial of carboplatin in the management of malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23337

7 January 2021

Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23337

7 January 2021

A Multicenter Phase II Study of Gemcitabine and Oxaliplatin for Malignant Pleural Mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23337

7 January 2021

A dose-finding study of gemcitabine and vinorelbine in advanced previously treated malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23337

7 January 2021

A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23337

7 January 2021

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23337

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23337

7 January 2021

A note on quantifying follow-up in studies of failure time

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23337

7 January 2021

Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23337

7 January 2021

Clinical trial designs for cytostatic agents: are new approaches needed?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23337

7 January 2021

Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23337

7 January 2021

Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma--The EORTC Lung Cancer Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23337

7 January 2021

Biology and management of malignant pleural mesothelioma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23337

7 January 2021

Identifiers

DOI

10.1002/CNCR.23337

1 reference

26 July 2017

1 reference